NEW YORK (GenomeWeb) – Invitae said after the close of the market on Monday that it plans to offer $50 million in shares of its common stock in a public offering.

Based on a stock price of $7.02 per share, the last reported sale price of its stock on March 23, Invitae said in a prospectus filed with the US Securities and Exchange Commission that it anticipates offering 7,122,507 shares. The company also plans to give underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.